Community post

Biochimpharm, a Georgian phage biotech company, has been awarded a $150,000 grant from the EU and the United Nations FAO to support production of PowerPhage, a phage cocktail product that targets Salmonella, E. coli and Shigella, for veterinary use. This grant, together with the $1M investment raised, is aimed to allow a 300% increase in the production of PowerPhage.